KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Asset Writedowns and Impairment (2016 - 2024)

Idexx Laboratories (IDXX) has 14 years of Asset Writedowns and Impairment data on record, last reported at $250000.0 in Q1 2024.

  • For Q1 2024, Asset Writedowns and Impairment changed N/A year-over-year to $250000.0; the TTM value through Dec 2024 reached $250000.0, down 83.15%, while the annual FY2024 figure was $250000.0, 83.15% down from the prior year.
  • Asset Writedowns and Impairment reached $250000.0 in Q1 2024 per IDXX's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.0 million in Q3 2020 and bottomed at $250000.0 in Q1 2024.
  • Average Asset Writedowns and Impairment over 4 years is $1.1 million, with a median of $1.4 million recorded in 2021.
  • Peak YoY movement for Asset Writedowns and Impairment: tumbled 47.52% in 2020, then tumbled 32.11% in 2021.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $508000.0 in 2020, then soared by 166.34% to $1.4 million in 2021, then rose by 9.68% to $1.5 million in 2023, then crashed by 83.15% to $250000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $250000.0 in Q1 2024, $1.5 million in Q4 2023, and $1.4 million in Q3 2021.